2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immune checkpoint therapy, specifically PD-1 blockade, has improved survival for patients with metastatic cancer, but not all patients respond to treatment.
- 1
- 2
Page 2 of 2
Results 11 - 11 of 11
Results 11 - 11 of 11